Understanding how REST affects treatment response in small cell lung cancer
Official title: Interrogating roles for REST in small cell lung cancer therapy response and resistance
Funded at Fred Hutchinson Cancer Center · NIH-11003759 · Data updated 2026-11-12
This study is looking at a protein called REST in small cell lung cancer to understand how it affects treatment success, especially in less common types, so that we can find better ways to help patients like you respond to therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | December 22, 2023 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $582,076 |
| NIH project number | 5R01CA287573-02 |
| Project ID | NIH-11003759 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with small cell lung cancer, especially those with low-neuroendocrine subtypes.
✕Less likely to help
Patients with non-small cell lung cancer or those who do not have the specific subtypes of SCLC being studied may not benefit from this research.
What this research studies
This research investigates the role of a protein called REST in small cell lung cancer (SCLC) and how it influences the effectiveness of cancer therapies. The study aims to explore different subtypes of SCLC, particularly focusing on those that are less understood, to determine how REST contributes to treatment resistance. By using advanced techniques like RNA sequencing and genetically engineered mouse models, researchers will analyze how REST affects the immune response and cancer cell behavior. Patients may benefit from insights that could lead to more effective treatment strategies tailored to specific cancer subtypes.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with small cell lung cancer, particularly those who currently have limited responses to existing therapies.
How similar studies have gone: Previous research has shown promising results in understanding the role of immune responses in cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Macpherson, David — Fred Hutchinson Cancer Center
- Study coordinator: Macpherson, David
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.